Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cyclopharm Limited (CYC.AX)
Kingsgrove, NSW, AU
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.43% | -1.39% | -2.07% | -15.98% | -10.13% | -27.55% | -40.83% | -64.50% | -72.59% | -8.15% | -59.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+17.2% ★ Q4'25: +59.2% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-23.1% Q4'25: -351.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-65.0% Q4'25: -68.7% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-56.3% Q4'25: -55.4% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-51.4% Q4'25: -100.9% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+7.0% Q4'25: +16.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.91× Q4'25: -0.44× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.19M
est: 13.70M (-3.7%)
|
13.40M
est: 13.50M (-0.7%)
|
14.08M
est: 13.60M (+3.5%)
|
14.68M
est: 14.00M (+4.8%)
|
17.70M
est: 17.10M (+3.5%)
|
23.22M
est: 22.60M (+2.7%)
|
26.34M
est: 24.06M (+9.5%)
|
27.57M
est: 28.00M (-1.5%)
|
32.33M
est: 32.30M (+0.1%)
|
36.60M
36.60M – 36.60M
+13.3% YoY
|
41.00M
41.00M – 41.00M
+12.0% YoY
|
51.00M
51.00M – 51.00M
+24.4% YoY
|
| EBITDA |
-1.35M
est: -4.86M (+72.3%)
|
-1.47M
est: 708.5K (-307.2%)
|
-1.38M
est: 91.1K (-1,612.7%)
|
-7.73M
est: -2.85M (-170.9%)
|
-5.79M
est: -3.73M (-55.3%)
|
-6.47M
est: -4.40M (-46.9%)
|
-3.84M
est: -8.45M (+54.6%)
|
-13.69M
est: -9.83M (-39.3%)
|
-16.41M
est: -11.34M (-44.7%)
|
-12.85M
-12.85M – -12.85M
-13.3% YoY
|
-14.39M
-14.39M – -14.39M
-12.0% YoY
|
-17.91M
-17.91M – -17.91M
-24.4% YoY
|
| EBIT |
725.2K
est: -5.44M (+113.3%)
|
-1.98M
est: 750.0K (-363.7%)
|
-2.38M
est: 142.7K (-1,766.4%)
|
-8.64M
est: -2.26M (-281.9%)
|
-6.55M
est: -6.79M (+3.6%)
|
-7.40M
est: -3.49M (-111.9%)
|
-4.77M
est: -9.43M (+49.4%)
|
-14.52M
est: -10.97M (-32.4%)
|
-18.18M
est: -12.66M (-43.7%)
|
-14.34M
-14.34M – -14.34M
-13.3% YoY
|
-16.06M
-16.06M – -16.06M
-12.0% YoY
|
-19.98M
-19.98M – -19.98M
-24.4% YoY
|
| Net Income |
-1.52M
est: -102.9K (-1,381.6%)
|
-35.5K
est: -1.58M (+97.8%)
|
-2.91M
est: -35.0K (-8,218.4%)
|
-6.04M
est: -3.07M (-96.7%)
|
-5.04M
est: -8.85M (+43.0%)
|
-6.61M
est: -6.94M (+4.8%)
|
-4.70M
est: -10.83M (+56.6%)
|
-13.20M
est: -11.67M (-13.1%)
|
-17.22M
est: -9.47M (-81.8%)
|
-16.52M
-16.52M – -16.52M
-74.4% YoY
|
-9.47M
-9.47M – -9.47M
+42.7% YoY
|
-4.52M
-4.52M – -4.52M
+52.3% YoY
|
| SGA |
6.18M
est: 7.12M (-13.1%)
|
6.64M
est: 9.03M (-26.5%)
|
7.02M
est: 9.14M (-23.2%)
|
6.62M
est: 12.52M (-47.1%)
|
7.98M
est: 16.36M (-51.2%)
|
9.78M
est: 19.32M (-49.4%)
|
10.03M
est: 12.72M (-21.1%)
|
24.62M
est: 14.81M (+66.3%)
|
16.11M
est: 17.08M (-5.7%)
|
19.35M
19.35M – 19.35M
+13.3% YoY
|
21.68M
21.68M – 21.68M
+12.0% YoY
|
26.97M
26.97M – 26.97M
+24.4% YoY
|
| EPS |
-0.02
est: 0.00 (-2,150.0%)
|
0.00
est: -0.02 (+97.4%)
|
-0.04
est: -0.05 (+19.2%)
|
-0.08
est: -0.10 (+21.9%)
|
-0.06
est: -0.09 (+34.5%)
|
-0.07
est: -0.04 (-83.8%)
|
-0.05
est: -0.10 (+48.5%)
|
-0.13
est: -0.11 (-22.6%)
|
-0.16
est: -0.09 (-86.0%)
|
-0.15
-0.15 – -0.15
-74.4% YoY
|
-0.09
-0.09 – -0.09
+42.7% YoY
|
-0.04
-0.04 – -0.04
+52.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James S. McBrayer BSPharm FAICD | Chief Executive Officer, MD, Company Secretary & Director | 570.2K | male |
| Mathew Farag | Chief Operating Officer | 458.1K | male |
| Jason Smith | Chief Financial Officer | 421.0K | male |
| Lynn McLauchlin | General Manager of Canada | 172.0K | male |
| Gary T. Somerville | Quality & Regulatory Manager | 152.0K | male |
| Sui Ling Cheah | Financial Controller | 63.7K | female |
| Niamh McAree | Head of Quality and Regulatory | — | female |
| Sally-Ann Cornelius | Head of Sales | — | female |
| Chris Quinn | Head of Service | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
